AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1095-1105

  Beltran, Pedro J ^a,d   Mitchell, Petia ^a   Chung, Young A ^a   Cajulis, Elaina ^a   Lu, John ^a   Belmontes, Brian ^a   Ho, Joanne ^b   Mei, Mei Tsai ^b   Zhu, Min ^c   Vonderfecht, Steven ^d   Baserga, Renato ^e   Kendall, Richard ^a   Radinsky, Robert ^a   Calzone, Frank J ^a  

^a Oncology Research Therapeutic Area   (United States)

^b Protein Science   (United States)

^c Quantitative Pharmacology   (United States)

^d AMGEN INC   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 479; CASPASE 3; GEMCITABINE; HUMAN MONOCLONAL ANTIBODY; INSULIN; RITUXIMAB; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PROTEIN BINDING; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66849140937     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1171     Document Type: Article

References (31)

1. Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer 2008;112:243-249
2. Burris HA, III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413 (Pubitemid 27251144)
3. Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty?. Oncologist 2008;13:562-576
4. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev 2004;4:505-518 (Pubitemid 38868620)
5. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995;55:2007-2011
6. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-244 (Pubitemid 32275588)
7. Rodon J, DeSantos V, Ferry RJ, Jr., Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008;7:2575-2588
8. Cui H, Niemitz EL, Ravenel JD, et al. Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res 2001;61:4947-4950 (Pubitemid 32681515)
9. Amikura K, Kobari M, Matsuno S. The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol 1995;17:139-146
10. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A 1992;89:5645-5649
11. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002;1:769-783 (Pubitemid 37361561)
12. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997;1332:F105-26.
13. Lawrence MC, McKern NM, Ward CW. Insulin receptor structure and its implications for the IGF-1 receptor. Curr Opin Struct Biol 2007;17:699-705. (Pubitemid 350180400)
14. Baserga R. The IGF-1 receptor in normal and abnormal growth. In: Dickson RB, Salomon DS, editors. Hormones and growth factors in development and neoplasia. New York: Wiley-Liss; 1998. p. 269-287
15. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Archiv Physiol Biochem 2008;114:23-37.
16. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/ IGF-I receptors in human cancer. Curr Pharmaceutical Des 2007;13:671-686 (Pubitemid 46510744)
17. Pandini G, Vigneri R, Costantino A, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999;5:1935-1944. (Pubitemid 29334478)
18. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989;49:6237-6241 (Pubitemid 20000915)
19. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer 2006;13 Suppl 1:S33-43.
20. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12. (Pubitemid 46206663)
21. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Exp Opin Ther Targets 2008;12:589-603.
22. Peruzzi F, Prisco M, Dews M, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999;19:7203-7215 (Pubitemid 29441900)
23. Bass J, Kurose T, Pashmforoush M, Steiner DF. Fusion of insulin receptor ectodomains to immunoglobulin constant domains reproduces high-affinity insulin binding in vitro. J Biol Chem 1996;271:19367-19375 (Pubitemid 26271608)
24. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66:8715-8721 (Pubitemid 44449188)
25. Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 1993;290:419-426 (Pubitemid 23094937)
26. Le Roith D, Scavo L, Butler A. What is the role of circulating IGF-I? Trends Endocrinol Metabol 2001;12:48-52.
27. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP- 751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-5840 (Pubitemid 47583908)
28. Juul A, Holm K, Kastrup KW, et al. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metabol 1997;82:2497-2502 (Pubitemid 27337863)
29. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 2002;1:1349-1353
30. Soos MA, Field CE, Lammers R, et al. A panel of monoclonal antibodies for the type I in sulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem 1992;267:12955-12963
31. Steele-Perkins G, Roth RA. Monoclonal antibody α IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding. Biochem Biophys Res Commun 1990;171:1244-1251